STING Agonist Exosomes for Brain Tumor Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroimmunological disorders such as gliomas and chronic infectious meningitis are inadequate, with glioblastoma multiforme having a survival rate of 14-15 months and limited efficacy of extracellular vesicles as drug delivery vehicles.
Innovation Solution
Administering a composition comprising extracellular vesicles, particularly exosomes, loaded with a STING agonist intrathecally or intratumorally to stimulate an immune response and treat neuroimmunological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatment options (surgery, radiation therapy, chemotherapy) are used for gliomas, then standard of care is established, but treatment efficacy is insufficient and survival rates remain low
Solution Approach 1:
The patent modifies the parameters of extracellular vesicle-based therapy by incorporating STING agonists into the extracellular vesicles, transforming them from passive delivery vehicles to active immunostimulatory agents. This parameter change enables the therapy to activate cGAS-STING signaling pathways in tumor cells and immune cells, thereby improving treatment efficacy and survival rates beyond traditional approaches
Solution Approach 2:
The patent creates a composite therapeutic system combining extracellular vesicles with STING agonists. This composite material integrates the delivery capabilities of extracellular vesicles with the immunostimulatory activity of STING agonists, achieving synergistic effects that enhance anti-tumor immunity and overcome the limitations of single-modality treatments
2Ease of manufacture
If extracellular vesicles are used as drug delivery vehicles, then advantages over traditional methods are achieved, but clinical efficacy remains limited
Solution Approach 1:
The patent uses STING agonists as intermediary molecules that bridge the extracellular vesicle delivery system with the immune response. The STING agonists act as mediators that, when delivered by extracellular vesicles, trigger cGAS-STING signaling pathways in target cells, thereby converting passive delivery into active therapeutic effect and improving clinical efficacy
Solution Approach 2:
The patent incorporates STING agonists into extracellular vesicles before administration, performing preliminary loading and positioning of the active agent. This preliminary action ensures that the STING agonist is already in place within the extracellular vesicle to immediately activate the cGAS-STING pathway upon delivery to target cells, enhancing the speed and effectiveness of the therapeutic response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances immune response and inflammatory modulation, potentially preventing glioma metastasis and improving survival rates by targeting brain tumors and meningitis.
Implementation Method 1
a stimulator of interferon genes protein (STING) agonist
Implementation Method 2
stimulator of interferon genes protein (STING) agonist
Data Source
AI summary
Provided herein are compositions comprising EV, e.g., exosome, which comprises STING agonists and methods of using such compositions for the treatment of neuroimmunological disorders. Methods of producing the compositions (e.g., EVs comprising a STING agonist) described herein are also provided.